United Kingdom· GB-APID-42173311000001106
Imjudo 300mg/15ml concentrate for solution for infusion vials
A tremelimumab product containing tremelimumab, registered in United Kingdom by AstraZeneca UK Ltd. The same ATC class is registered in 16 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Tremelimumab is registered in 16 of 19 countries.
Countries holding a registration under ATC L01FX20 (tremelimumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Tremelimumab · ATC L01FX20
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tremelimumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tremelimumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$779.98
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Tremelimumab
- Manufacturer
- AstraZeneca UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX20
- ATC class
- Tremelimumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5000456037211
- gtin05000456037211
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tremelimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumImjudo 20 mg/mlAstraZeneca
- United StatesIMJUDOAstraZeneca Pharmaceuticals LP
- FinlandIMJUDOAstraZeneca AB
- CzechiaIMJUDOAstraZeneca AB, Södertälje
- Japanトレメリムマブ（遺伝子組換え）アストラゼネカ
- SwedenIMJUDO 20 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- SwitzerlandIMJUDO
- NetherlandsImjudo 20 mg/ml, concentraat voor oplossing voor infusieAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imjudo
- Liechtenstein · Imjudo
- Norway · Imjudo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9a23203-e141-4f7e-a6dd-a73299d2d81d GET /v1/drugs/e9a23203-e141-4f7e-a6dd-a73299d2d81d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42173311000001106",
"desc": "Imjudo 300mg/15ml concentrate for solution for infusion vials (AstraZeneca UK Ltd)",
"form": "Solution for infusion",
"vpid": "42237711000001100",
"source": "dmd",
"vtm_id": "42220011000001101",
"strength": "20 mg",
"substance": "Tremelimumab",
"ingredient": "Tremelimumab",
"supplier_code": "3583301000001102"
}See everything about tremelimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.